Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of TQ05105 in Hepatic Impairment and Healthy Subjects
NCT07480824Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rovadicitinib in myelofibrosis (MF) (3 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak concentration at 48 hours and Area under the concentration-time curve at 48 hours. Started Apr 2026; status: recruiting.
02
Drugs
rovadicitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07480824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07480824.